News
Join us at Biofit 2015 in december in Strasbourg
We will be attending BioFIT on 1st and 2nd of December 2015, placed in Strasbourg. BioFIT is one of the best european place to be for B to B meetings
We will be attending BioFIT on 1st and 2nd of December 2015, placed in Strasbourg. BioFIT is one of the best european place to be for B to B meetings
Our CEO, Nathalie, participated last month at the 2015 edition of the “Femmes de l’économie” contest for the west of France.
The data analysis and statistics, especially the Z-score that everybody knows, need to be reviewed. Guyon et al boast Φ-score.
Complexify cell models to improve relevance of the phenotyic assay in order to find new drugs more efficient is that’s what everyone strives to do.
The Neurobiology Laboratory of cellular interactions and neurophysiopathology demonstrates for the first time the contribution of the MT5-MMP protease in the development of Alzheimer’s disease in a mouse model
In this article, authors emphasize the importance of standardisation in the development of HCS.
This summer has been very studious for us with the development and validation of new tests in the oncology field.
We were present in the innovation zone of Drug Discovery 2015 congress last week in Telford. We had the opportunity to present our work with two posters.
Join us for the next ELRIGfr conference in Brussels, the 14th & 15th of october.
Thomas Kirchhausen, Eric Betzig et al. publish an article in Sciences about SIM (structured illumination microscopy) and the observation of moving molecules inside cells. The incredible spatial and time resolution give the opportunity to see for exemple proteins which pass the cell membrane.
We just begin a test period of the Operetta “High Content Imaging System” from Perkin Elmer. First impressions are very goods, especially using confocal option for 3D imaging.
Vas Narasimhan, global head development at Novartis Pharmaceuticals talks about the importance of digital nowadays in pharmaceutical companies. He also emphasis the need to combine different cells therapies to efficiently cure complex diseases. Of course for us, it’s also a confirmation of HCS future developments to test the efficiency of these combinations.
We will be present in the “innovation zone” during the Drug discovery 2015 in Telford the 2nd and 3rd of September in Telford.
It was really interesting to be present at the AFSSI’s “universités d’été”. About 160 business heads of CRO (contract research organisation) in biotechnology area were present. We were also lucky to present our business during the elevator pitch, 5 min to convince, during the 2nd day.
It was a pleasure for us to welcome Antoine at HCS Pharma for a 6 week internship focused on statistics interpretation improvement.
HCS Pharma a reçu l’agrément CIR (Crédit Impôt Recherche) du Ministère de L’Enseignement Supérieur et de la Recherche. Cette accréditation signe la reconnaissance par l’administration française de notre capacit
We will be present in Dijon the 7th and 8th July for “les universités d’été” organised by AFSSI, a series of round-table to understand the needs of technology entrepreneurs in life sciences, coupled with an international business convention bringing together key industry players.
The author has reported te use of phenotypic screening to find coumpound which has neuronal differenciation effect of stem cells.
After a license degree in Cellular Biology and physiology Méryl Roudaut is currently studying for his second year of master degree at Université Paul Sabatier (UPS) Toulouse III
Now, with cell imaging, cardiotoxicity assay can be performed in vitro in higher throughput and thus this assay can be used in the early phase of research.
Aviv Regev at the Broad Institute, in Cambridge, use fluidic systems to separate cells and submits them to detailed genetic analysis, at the rate of thousands per day. The goal is to build a comprehensive cellular atlas of the human, based on gene expression profile.
As we are a active part of Frenchtech mouvement in Rennes, we also participate to the french startup assembly.
This is an interesting summary of the strategy adopted by pharmaceutical industry presented by Steve Rees, the Vice-President of screening sciences and sample management at Aztrazeneca. This interview was realised by selectscince last month.